Ex Vivo-Generated Tolerogenic Dendritic Cells: Hope for a Definitive Therapy of Autoimmune Diseases

Author:

Jonny 123ORCID,Sitepu Enda Cindylosa1,Nidom Chairul A.45ORCID,Wirjopranoto Soetojo6,Sudiana I. Ketut6,Ansori Arif N. M.4,Putranto Terawan Agus1

Affiliation:

1. Indonesia Army Cellcure Center, Gatot Soebroto Central Army Hospital, Jakarta 10410, Indonesia

2. Faculty of Medicine, University Prima Indonesia, Medan 20118, Indonesia

3. Faculty of Military Medicine, Indonesia Defense University, Jakarta 16810, Indonesia

4. Professor Nidom Foundation, Surabaya 60236, Indonesia

5. Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya 60115, Indonesia

6. Faculty of Medicine, Universitas Airlangga, Surabaya 60115, Indonesia

Abstract

Current therapies for autoimmune diseases are immunosuppressant agents, which have many debilitating side effects. However, dendritic cells (DCs) can induce antigen-specific tolerance. Tolerance restoration mediated by ex vivo-generated DCs can be a therapeutic approach. Therefore, in this review, we summarize the conceptual framework for developing ex vivo-generated DC strategies for autoimmune diseases. First, we will discuss the role of DCs in developing immune tolerance as a foundation for developing dendritic cell-based immunotherapy for autoimmune diseases. Then, we also discuss relevant findings from pre-clinical and clinical studies of ex vivo-generated DCs for therapy of autoimmune diseases. Finally, we discuss problems and challenges in dendritic cell therapy in autoimmune diseases. Throughout the article, we discuss autoimmune diseases, emphasizing SLE.

Funder

Indonesia Army Cellcure Center

Publisher

MDPI AG

Reference64 articles.

1. Type 1 diabetes mellitus;Katsarou;Nat. Rev. Dis. Primers,2017

2. Multiple sclerosis;Filippi;Nat. Rev. Dis. Primers,2018

3. Rheumatoid arthritis;Smolen;Nat. Rev. Dis. Primers,2018

4. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management;Ameer;Cureus,2022

5. Pathogenesis of autoimmune disease;Pisetsky;Nat. Rev. Nephrol.,2023

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3